Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.
about
The Evolution of Cystic Fibrosis CareColistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapyCurrent and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its SymptomsEradication of Burkholderia cepacia Using Inhaled Aztreonam Lysine in Two Patients with Bronchiectasis.Patient-specific modeling of regional antibiotic concentration levels in airways of patients with cystic fibrosis: are we dosing high enough?Pro-moieties of antimicrobial peptide prodrugs.The cystic fibrosis microbiome in an ecological perspective and its impact in antibiotic therapy.Sustained Pulmonary Delivery of a Water-Soluble Antibiotic Without Encapsulating CarriersManagement of pulmonary exacerbations in cystic fibrosis: still an unmet medical need in clinical practice.Long-term safety and efficacy of tobramycin in the management of cystic fibrosis.Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacinPotential of host defense peptide prodrugs as neutrophil elastase-dependent anti-infective agents for cystic fibrosis.Physicochemical properties of mucus and their impact on transmucosal drug delivery.Treatment of pseudomonas and Staphylococcus bronchopulmonary infection in patients with cystic fibrosis.Improvements in symptomatic treatment strategies for cystic fibrosis: delivering CF care in the 21st century
P2860
Q26999299-32082F8A-D8C3-4446-B1DD-C350EEC495F1Q27014993-CE148013-F43B-4AE4-B584-80643A5C929BQ28077411-A8E59D2B-7051-4330-B80D-187C088F905BQ34245276-F1759401-135A-4CF7-B78F-D4DC94F06FF1Q35143793-CC20DFD7-7167-49AB-AA81-65C021C69AF0Q35543287-5B16E03F-B77A-414C-83D7-F92D3A79A777Q35861377-558BC49B-5CA5-4627-9346-FC1BE82C1A24Q36553897-ECBEDA22-52DE-4BE9-9287-1DD417CADF36Q38360133-F34E6186-847B-42C3-A8F7-E8ADF036E5DEQ38384994-B54728C6-8C68-4D06-B71A-632131C36868Q38630919-B380DA36-A2B3-4EDE-AC2E-FF5C61056558Q38634682-308E3C40-A3FC-447A-9433-A028C1E4562EQ41907587-FFDC7DEF-B23B-4A62-A168-AE9728D08325Q47791593-C1572A1E-52CE-4D29-B94C-7F0E5EB0AB34Q54318026-3CC16EC8-2823-408F-AE70-F16137B6EB79Q57913519-D376FC27-D275-486E-8779-C13DCF8FB7DA
P2860
Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Inhaled antibiotics for the tr ...... randomised controlled trials.
@en
type
label
Inhaled antibiotics for the tr ...... randomised controlled trials.
@en
prefLabel
Inhaled antibiotics for the tr ...... randomised controlled trials.
@en
P2093
P2860
P1476
Inhaled antibiotics for the tr ...... randomised controlled trials.
@en
P2093
Adelaida Lamas
Casilda Olveira
Dolores Pastor
Esther Quintana
Josep Mensa
Rafael Cantón
Rosa M Girón
P2860
P304
P356
10.1517/14656566.2013.790366
P407
P577
2013-04-16T00:00:00Z